Peripherally acting mu-opioid antagonists (PAMORA). PAMORAs indicated for the treatment of OIC include naloxegol, naldemedine, and methylnatrexone. These agents are opioid antagonists selective to ...

Symproic significantly improved bowel function and frequency of spontaneous bowel movements in patients receiving opioids compared to placebo. The study highlighted a 47.6% difference in bowel ...

Shionogi today announced pivotal phase III study (COMPOSE I) results showing that once-daily treatment with naldemedine significantly improved opioid-induced constipation (OIC) compared to placebo in ...

First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer This multicenter, ...

May 12, 2009 (San Diego, California) — Constipation is a well-known adverse effect of opioid analgesics but often goes undiagnosed because patients can be reluctant to talk about it, experts warn.

Pharmacology: The use of opioid analgesics can lead to constipation due to their effect on intestinal smooth muscle and their interference with the bowel’s normal elimination function.

PALM SPRINGS, California — A peripherally acting oral μ-opioid receptor antagonist is superior to placebo in treating opioid-induced constipation (OIC) and doesn't reduce the analgesic effect of ...

Tsukuba, Japan—Pain relief for patients with cancer is crucial, and opioids, such as morphine, play a vital role. However, constipation, which negatively affects the patient's quality of life, is a ...

The Food and Drug Administration recently approved the tablet form of Relistor to treat opioid-induced constipation. Relistor, produced by Tarrytown, N.Y.-based Progenics Pharmaceuticals, was ...

LAVAL, QC / ACCESSWIRE / December 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), alongside the U.S. Pain Foundation ...

NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals Inc. (NAS: SGYP) today announced presentations on plecanatide and SP-333, its proprietary guanylate cyclase-C (GC-C) agonists in development for ...